Clinical Trials Browser

Central Nervous System Neoplasms × Imatinib Mesylate × Sarcoma × Clear all

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT00010049 2018-06-27

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Phase 1/2 Completed

105 enrolled

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Phase 1 Completed

37 enrolled

CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00354068 2013-03-28

Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

Phase 1 Completed

65 enrolled

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00039364 2012-07-24

Imatinib Mesylate in Treating Patients With Gliomas

Phase 2 Completed

112 enrolled

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

Clinical Trials

Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma

Imatinib Mesylate in Treating Patients With Gliomas